Protalix BioTherapeutics, Inc. (PLX)
Grows medicines in plant cells to treat rare genetic diseases.
$2.33-0.03%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+60.7%
The outlook
PLX is trading above both its 50- and 200-day moving averages, positioning it in the middle of its 52-week range. Analyst coverage shows an average price target approximately 3.7x the current price, though such wide gaps between targets and current trading levels warrant careful scrutiny. The stock carries a trailing P/E of 12.9 and a bullish lean overall.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range52% of the way from its 52-week low to high
Price targetAvg target +372% vs current price
Analyst price target
~12-month · 2 analysts$11.00average target+372.1% vs now
Now $2.33
Low $10.00High $12.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$187.7M
52-wk high
$3.19
52-wk low
$1.41
50-day avg
$2.18
200-day avg
$2.22
Trailing P/E
12.9